View all publications on PubMed »
Allen-Gondringer A., Gau D., Dutta P., Roy P. (2024) Haplo-insufficiency of Profilin1 in vascular endothelial cells is beneficial but not sufficient to confer protection against experimentally induced atherosclerosis. Cytoskeleton. doi: 10.1002/cm.21859. PMID: 38623956
Gau D.*, Allen A., Daoud A., Kunkel J., Lee S., Sagan A., Boone D., Osmanbeyoglu H., Roy P. (2023) Vascular endothelial profilin-1 Inhibition suppresses tumor progression in renal cancer. J. Biol. Chem 299(8):105044. PMID: 37451478. * corresponding author
Gau D., Vignaud L., Francoeur P., Koes D., Guillonneau X., Roy P. (2021). Inhibition of ocular neovascularization by novel anti-angiogenic compound. Exp Eye Res 213:108861 doi: 10.1016/j.exer.2021.108861 PMID: 34822853, PMCID: PMC8845053
Allen A.*, Gau D.*, Francoeur P., Sturm J., Wang Y., Martin R., Maranchie J. Duensing A., Kaczorowski A., Duensing S., Wu L., Lotze M.T., Koes D., Storkus W., Roy P (2020) Actin-binding protein profilin1 promotes aggressiveness of clear cell renal cell carcinoma cells. J. Biol. Chem Nov 13; 295(46):15636-15649. doi: 10.1074/jbc.RA120.013963. PMID: 32883810. * co-first author
Gau D., Lewis T., McDermott L., Wipf P., Koes D., Roy P. (2018) Structure-based virtual screening identifies a small molecule inhibitor of the profilin1-actin interaction. J. Biol Chem Feb 16; 293(7):2606-2616. PMID: 29282288 PubMed Central PMCID: PMC5818201.